NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NOVAVAX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.82−0.44 (-3.91%)
Close on Oct 19, 2026
- Market cap
- $1.78B
- P/E (TTM)
- –
- Dividend yield
- –
Novavax statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Novavax | Industry median |
|---|---|---|
| Market Cap | $1.78B | $163.01M |
| Enterprise Value | $1.07B | $86.72M |
| PS Ratio | 4.31 | 3.58 |
Enterprise value
| Measure | Novavax | Industry median |
|---|---|---|
| EV / Sales | 2.57 | 2.42 |
Income (trailing twelve months)
| Measure | Novavax | Industry median |
|---|---|---|
| Revenue | $413.80M | $57.94M |
| Gross Profit | $325.26M | $90.47M |
| Operating Income | -$234.12M | -$21.44M |
| Pretax Income | -$245.32M | -$14.45M |
| Net Income | -$247.73M | -$22.46M |
| EBITDA | -$215.91M | -$16.91M |
| EPS (Diluted) | -$1.54 | -$0.83 |
Margins
| Measure | Novavax | Industry median |
|---|---|---|
| Gross Margin | 78.6% | 52.3% |
| Operating Margin | -56.6% | -44.5% |
| Pretax Margin | -59.3% | -13.0% |
| Profit Margin | -59.9% | -39.2% |
| EBITDA Margin | -52.2% | -31.3% |
Returns
| Measure | Novavax | Industry median |
|---|---|---|
| Return on Assets (ROA) | -21.6% | -41.0% |
| Return on Capital Employed (ROCE) | -37.5% | -37.8% |
Growth
| Measure | Novavax | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -61.6% | 6.01% |
| Net Income Growth (YoY) | -158.6% | -37.7% |
| EPS Growth (YoY) | -167.5% | -29.2% |
| Revenue Growth (3Y CAGR) | -17.2% | 2.25% |
| Revenue Growth (5Y CAGR) | 18.8% | 6.42% |
Balance sheet
| Measure | Novavax | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $719.34M | $62.42M |
| Net Cash (Debt) | $719.34M | $15.68M |
| Net Cash Per Share | $4.36 | $0.66 |
| Equity (Book Value) | -$190.71M | $48.79M |
| Book Value Per Share | -$1.16 | $1.36 |
| Tangible Book Value | -$303.25M | $23.06M |
| Working Capital | $440.52M | $75.77M |
Financial position
| Measure | Novavax | Industry median |
|---|---|---|
| Current Ratio | 2.33 | 3.30 |
| Quick Ratio | 2.23 | 2.39 |
| Interest Coverage | -10.69 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Novavax | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.90M | -$12.35M |
Efficiency
| Measure | Novavax | Industry median |
|---|---|---|
| Asset Turnover | 0.36 | 0.38 |
| Inventory Turnover | 8.75 | 2.67 |
| Revenue Per Employee | $552.47K | $398.96K |
| Profits Per Employee | -$330.75K | -$703.34K |
| Employee Count | 749 | 74 |
Dividends and yields
| Measure | Novavax | Industry median |
|---|---|---|
| Earnings Yield | -13.9% | -22.9% |
Shares
| Measure | Novavax | Industry median |
|---|---|---|
| Shares Outstanding | 164,946,000 | 58,179,650 |
| Shares Change (YoY) | 0.42% | 11.1% |
| Shares Change (QoQ) | 0.24% | 0.54% |
| Float | 149,783,000 | 49,173,100 |
| Shares Held by Insiders | 9.19% | 11.6% |
| Shares Held by Institutions | 71.2% | 59.4% |
Taxes
| Measure | Novavax | Industry median |
|---|---|---|
| Income Tax | $2.42M | $91.50K |
Scores
| Measure | Novavax | Industry median |
|---|---|---|
| Altman Z-Score | -5.67 | -0.28 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | 0.44 | -2.62 |
Calculated by StockData from Novavax's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.